



SmartPA Criteria Proposal

Drug/Drug Class:	Macrolides PDL Edit
First Implementation Date:	May 25, 2005
Revised Date:	October 1, 2020
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Macrolide antibiotics reversibly bind to the P-site of the 50S ribosomal subunit of susceptible organisms and may inhibit RNA-dependent protein synthesis. They may be bacteriostatic or bacteriocidal, depending on such factors as drug concentration. There are currently four macrolides available in the U.S. They are all equally efficacious for the treatment of most community-acquired infections, but some have better tolerability and allow for once to twice daily dosing.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	<ul style="list-style-type: none">• Azithromycin Tabs/Susp• Clarithromycin Tabs/Susp• Erythromycin Base DR Caps• Erythromycin Ethylsuccinate Susp/Tabs	<ul style="list-style-type: none">• Clarithromycin ER• E.E.S. 200[®] Susp• E.E.S. 400[®]• EryPed[®]• Ery-Tab[®]• Erythrocin[®] Stearate• Erythromycin Base Tabs• Erythromycin Base DR Tabs• PCE[®]• Zithromax[®]
--------------------------------------	--	---

Type of Criteria: ☐ Increased risk of ADE
☐ Appropriate Indications

☒ Preferred Drug List
☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Macrolides
- Age range: All appropriate MO HealthNet participants

SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 2 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

Required Documentation

Laboratory Results:

MedWatch Form:

Progress Notes:

Other:

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)

Rule Type: PDL

Default Approval Period

1 year

References

1. Evidence-Based Medicine and Fiscal Analysis: "Macrolides - Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; May 2020.
2. Evidence-Based Medicine Analysis: "Macrolides", UMKC-DIC; March 2003, Updated April 2020.
3. Drug Effectiveness Review Project: Drug Class Review on Macrolides; Oregon Health & Science University; August 2006, updated July 2014 (scan).
4. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
5. USPDI, Micromedex; 2020.
6. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.